Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020
Open Access
- 5 September 2020
- journal article
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 19 (4)
- https://doi.org/10.15829/1728-8800-2020-2630
Abstract
The pandemic of the novel coronavirus infection (COVID-19), caused by SARS‑CoV‑2, has become a challenge to healthcare systems in all countries of the world. Patients with comorbidity are the most vulnerable group with the high risk of adverse outcomes. The problem of managing these patients in context of a pandemic requires a comprehensive approach aimed both at the optimal management in self-isolated patients not visiting medical facilities, and management of comorbidities in patients with COVID-19. The presented consensus covers these two aspects of managing patients with cardiovascular disease, diabetes, chronic obstructive pulmonary disease, gastrointestinal disease, and also pay attention to the multiple organ complications of COVID-19.Keywords
This publication has 98 references indexed in Scilit:
- 2015 ESC GUIDELINES FOR THE DIAGNOSIS AND MANAGEMENT OF PERICARDIAL DISEASESRussian Journal of Cardiology, 2016
- Clinical Profile and Influences on Outcomes in Patients Hospitalized for Acute PericarditisJournal of the American College of Cardiology, 2014
- Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial DiseasesEuropean Heart Journal, 2013
- Development and Validation of a Risk Score to Predict QT Interval Prolongation in Hospitalized PatientsCirculation: Cardiovascular Quality and Outcomes, 2013
- Management of Recurrence of Symptoms of Gastroesophageal Reflux Disease: Synergistic Effect of Rebamipide with 15 mg LansoprazoleDigestive Diseases and Sciences, 2010
- Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptorsKidney International, 2005
- Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2Gut, 2005
- Pharmacological characterization of rebamipide: its cholecystokinin CCK1 receptor binding profile and effects on Ca2+ mobilization and amylase release in rat pancreatic acinar cellsEuropean Journal of Pharmacology, 2004
- Review article: rebamipide and the digestive epithelial barrierAlimentary Pharmacology & Therapeutics, 2003
- Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzymeFEBS Letters, 2002